Laurent Arthaud

ENYO Pharma is a clinical stage company with an innovative approach inspired by viruses. Our biotech mimics virus strategy to modulate host cellular functions with multiple applications. We develop new drug candidates in multiple indications such as infectious diseases (e.g. HBV), metabolic diseases (e.g. NASH) and oncology. Our main candidate Vonafexor (EYP001, FXR agonist) is in Phase 2 for both chronic hepatitis B and Non-Alcoholic Steato-Hepatitis. Our second candidate, EYP002, is currently in preclinical studies. Initially developed against influenza virus, it has a mitochondrial cellular target which leads ENYO Pharma to explore new indications such as oncology or metabolic diseases. Thanks to the MIMESIS project, funded by European Union’s Horizon 2020 Research and Innovation Program, ENYO Pharma has a portfolio of early molecules for various indications (RSV, Immunogenic Cell Death, Zika virus, rhinovirus, influenza virus and Mycobacterium tuberculosis) ENYO Pharma is also a member of the CARE consortium (Corona Accelerated R&D in Europe), the largest European research initiative addressing the drug discovery challenges of COVID-19, funded by IMI 2 JU. ENYO Pharma is currently based in Lyon, France and in Melbourne, Australia.

Born from the scientific laboratories of the prestigious CEA, deeptech Aledia is today at the forefront of a technological revolution. After a decade of innovation and development, we are shaping the future of display with our 3D WireLED™ technology. We aim to be the undisputed global leader in MicroLED for next-generation displays by combining technological innovation and manufacturing excellence. We envision a future where our disruptive WireLED™ technology equips a multitude of devices, making the visual experience more intense and realistic. Visit our website at www.aledia.com to know more !

Calyxt is a plant-based synthetic biology company leveraging its PlantSpring™ technology platform to engineer innovative ingredients and products to help customers meet their sustainability goals and supply chain challenges. Calyxt is located in Roseville, MN, and is listed on the Nasdaq market (ticker: CLXT). For further information please visit our website at www.calyxt.com. See our community guidelines: http://bit.ly/2SHuhnc

"Innovative medicine for everyone, everywhere"​ Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia operates in the diabetes and metabolic disease field. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. For more information, visit our website: www.adocia.com For careers offers, please click to the following link : http://offres.adocia.com/en

Tikehau Capital is a global alternative asset management group with €50.6 billion of assets under management (at 31 March 2025). Tikehau Capital has developed a wide range of expertise across four asset classes (credit, real assets, private equity and capital markets strategies) as well as multi-asset and special opportunities strategies. Tikehau Capital is a founder-led team with a differentiated business model, a strong balance sheet, proprietary global deal flow and a track record of backing high quality companies and executives. Deeply rooted in the real economy, Tikehau Capital provides bespoke and innovative alternative financing solutions to companies it invests in and seeks to create long-term value for its investors, while generating positive impacts on society. Leveraging its strong equity base (€3.2 billion of shareholders’ equity at 31 December 2024), the firm invests its own capital alongside its investor-clients within each of its strategies. Controlled by its managers alongside leading institutional partners, Tikehau Capital is guided by a strong entrepreneurial spirit and DNA, shared by its 747 employees (at 31 March 2025) across its 17 offices in Europe, the Middle East, Asia and North America. Tikehau Capital is listed in compartment A of the regulated Euronext Paris market (ISIN code: FR0013230612; Ticker: TKO.FP). For more information, please visit: www.tikehaucapital.com.

Tikehau Ace Capital invests with a sector-focused approach, active in Industrials and Technology. The firm builds partnerships with large corporates (including Airbus, Safran, Dassault Aviation, Thales, EDF, Naval Group, Sopra Steria), which invest in its funds and maintain an ongoing dialogue with the firm, enabling Ace to take a differentiated approach to investing. Ace provides capital for businesses going through transformation, with the ability to invest with a variety in Venture & Growth Capital, buyout, and restructuring situations. We focus on companies with a proven expertise in their market, and with high and resilient intrinsic value, but which require transformation to deliver on their potential. We act as a strategic partner to management as we transform operations, and restructure/grow the business both organically and through external growth. Ace is active throughout Europe and North America. The firm has offices in Paris, Toulouse, and accesses the global network of Tikehau Capital offices (London, Milan, Madrid, Brussels, New York, Singapore, Tokyo and Seoul). Investment strategies overview: - Venture & Growth Capital: investment in high/hyper growth companies raising money in Series A through C, active in the Cybersecurity and Digital Trust verticals o Investment amount: up to €50m o Sector of focus: Technology (e.g. Cybersecurity, Digital Trust) - Support Capital: development capital / special opportunities (minority or control) investments in companies requiring capital to stabilise and or grow operations o Investment amount: up to €50m o Sector of focus: Industrials (e.g. Aerospace, Defence) - Platform Capital: development capital / special opportunities (minority or control) investments in companies requiring capital to stabilise and or grow operations o Investment amount: €50-200m o Sector of focus: Industrials (e.g. Aerospace, Defence)

IntegraGen is an OncoDNA group company specializing in the genomics of cancer and rare genetic diseases. Backed by highly competent and qualified teams, IntegraGen is a leading player in DNA sequencing services and genomic data interpretation software. The company runs one of the largest NGS labs in France and operates for research institutes of excellence. As part of OncoDNA group, IntegraGen leverages the power of next generation sequencing with the mission of delivering the promise of precision medicine to patients. IntegraGen has about 50 employees and generated €9 million of revenue in 2020. Based in France, IntegraGen is also present in the United States and is part of the OncoDNA group which works with an international network of 35 distributors. The Group also provides biomarker testing and clinical interpretation tools to guide treatment and monitoring of late stage solid tumors and accelerate the development of new cancer drugs. IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 - Mnemo: ALINT - Eligible PEA-PME).

Biocitech is a center for healthcare, biotech and environmental companies. It provides on-site support to residents from inception through to business maturity. Services are specifically designed to help firms grow and to publicize their development. Biocitech is the only science and technology center in the Paris area that is ICPE certified. It offers a comprehensive and flexible range of services that include technical buildings, multi-technical services and support services. ICPE certification provides entrepreneurs with secure premises of a high technological standard. The unique combination gives firms the benefit of specialized resources that cost less because they are pooled. Biocitech is located close to Raymond Queneau Paris subway station and is only 20 minutes from Charles de Gaulle airport. The center is market-oriented; the great majority of its residents generate revenues from the sale of products or services. Biocitech firms complement one another by generating strong synergies and numerous collaborations. Along with other organizations in the Paris area, Biocitech is a key element in the Medicen Paris Region network, the Greater Paris region’s world-class competitiveness hub for health and new therapies.

At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization.

ENYO Pharma is a clinical stage company with an innovative approach inspired by viruses. Our biotech mimics virus strategy to modulate host cellular functions with multiple applications. We develop new drug candidates in multiple indications such as infectious diseases (e.g. HBV), metabolic diseases (e.g. NASH) and oncology. Our main candidate Vonafexor (EYP001, FXR agonist) is in Phase 2 for both chronic hepatitis B and Non-Alcoholic Steato-Hepatitis. Our second candidate, EYP002, is currently in preclinical studies. Initially developed against influenza virus, it has a mitochondrial cellular target which leads ENYO Pharma to explore new indications such as oncology or metabolic diseases. Thanks to the MIMESIS project, funded by European Union’s Horizon 2020 Research and Innovation Program, ENYO Pharma has a portfolio of early molecules for various indications (RSV, Immunogenic Cell Death, Zika virus, rhinovirus, influenza virus and Mycobacterium tuberculosis) ENYO Pharma is also a member of the CARE consortium (Corona Accelerated R&D in Europe), the largest European research initiative addressing the drug discovery challenges of COVID-19, funded by IMI 2 JU. ENYO Pharma is currently based in Lyon, France and in Melbourne, Australia.

Born from the scientific laboratories of the prestigious CEA, deeptech Aledia is today at the forefront of a technological revolution. After a decade of innovation and development, we are shaping the future of display with our 3D WireLED™ technology. We aim to be the undisputed global leader in MicroLED for next-generation displays by combining technological innovation and manufacturing excellence. We envision a future where our disruptive WireLED™ technology equips a multitude of devices, making the visual experience more intense and realistic. Visit our website at www.aledia.com to know more !

Calyxt is a plant-based synthetic biology company leveraging its PlantSpring™ technology platform to engineer innovative ingredients and products to help customers meet their sustainability goals and supply chain challenges. Calyxt is located in Roseville, MN, and is listed on the Nasdaq market (ticker: CLXT). For further information please visit our website at www.calyxt.com. See our community guidelines: http://bit.ly/2SHuhnc

Bpifrance, Banque publique dinvestissement, accompagne les entreprises, de lamorçage jusquà la cotation en bourse, du crédit aux fonds propres. Interlocuteur privilégié, Bpifrance propose dans chaque région des solutions de financement ou d’investissement adaptées à chaque étape de la vie des entreprises. Banque partenaire des entrepreneurs, Bpifrance les accompagne durablement pour soutenir leur croissance et leur compétitivité. Les équipes sont au cœur des régions, sur l’ensemble du territoire, à travers plus de 50 implantations régionales.